ALLR Allarity Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ALLR matters now
Allarity Therapeutics, Inc. (ALLR) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.17 with -2.92% on the session and $18.5M in market capitalization; recent performance reads 1-month -4.03% and YTD +32.41%.
The latest financial table shown here is Q1 2026, with revenue of $25.0K, net income of $-2.8M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -73.4%.
The latest indexable market news headline is "Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Jensen Thomas filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.30
P/S
65.95
EV/EBITDA
-2.23
DCF Value
$1.25
FCF Yield
-73.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
107.5%
Operating Margin
-3552.8%
Net Margin
-3260.6%
ROE
-109.9%
ROA
-32.2%
ROIC
-43.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $25.0K | $-2.8M | $-0.17 |
| Q4 2025 | $320.0K | $-3.4M | $-0.21 |
| FY 2025 | $320.0K | $-11.2M | $-0.78 |
| Q3 2025 | $0.00 | $-2.8M | $-0.19 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.38
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.